UK Clears Casgevy Gene Therapy for Children as Young as Five; NHS Funding Unresolved
· techtimes.com · popularity 20/100 · 0 similar stories today · Genetics, Genomics & Biotech (Science)
Read the original at techtimes.com →
Summary
Casgevy gene therapy for UK children was extended to patients aged five and over by the MHRA on October 29, 2026; a milestone for sickle cell disease and beta-thalassemia patients, but NHS access for the newly eligible five-to-eleven cohort requires a separate NICE appraisal that has not yet started.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 6.